Myönnetyt tuet
Säätiön rahoittaa Suomessa veri- ja syöpätauteja sairastaville lapsille annetun lääketieteellisen hoidon kehitystyötä sekä perustutkimusta kansallisella ja kansainvälisellä tasolla.
2022
PP2A in medulloblastoma therapy resistance: novel opportunities for targeted therapeutics, grant of 30 000 euros.
Personal crisis and cancer predispose syndromes (PeCCaPS), genomitiedon psykologiset vaikutukset, grant of 28 000 euros.
An international prospective trial for children with a typical teratoid/rhabdoid tumours (ATRT) including
a randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to
focal radiotherapy, grant of 65 076 euros.
SIOP YCMB-LR: Prospective international SIOPE/CONNECT/NEXT phase-III trial to improve neurocognitive outcomes in young children with low-risk medulloblastoma. Prospektiivinen kansainvälinen pienten lasten medulloblastooman kliininen lääketutkimus, grant of 78 269 euros.
SIOP PNET5 MB v13: Medulloblastooman postoperatiivinen hoito, kansainvälinen prospektiivinen tutkimus yli 3 -5 -vuotiailla lapsilla ja nuorilla, grant of 64 844 euros.
SIOPEN jäsenmaksu 1000 euroa/vuosi, 2 vuotta. Suomi on ollut mukana SIOP:n korkeariski neuroblastooman hoitoprotokollissa,
joihin pääsyn edellytyksenä on kuuluminen SIOPEN:iin, grant of 2 000 euros.
Significance and specific targeting of SUMO pathway in Neuroblastoma, grant of 15 000 euros.
Lapsuusiän leukemian luustovaikutukset – kudostason mekanismit, grant of 15 000 euros.
2021
Research on Thrombocytopenia and aplastic anaemia of children treated in Finland, grant of 20 000 euros.
Research on AT/RT tumors’ epigenetic regulators, grant of 6 000 euros.
Research on FaR-RMS – An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma, grant of 86 600 euros.
Research on A registry for soft tissue sarcoma and other soft tissue tumours in children, adolescents, and young adults, grant of 76 250 euros.
Research on Functional Precision Medicine For Pediatric Solid Tumors, grant of 80 000 euros.
Research on Mechanisms causing pediatric kidney cancer Wilms tumor, grant of 37 000 euros.
Research on the diagnosis and treatment of children, adolescents and young adults with ependymoma, grant of 57 980 euros.
Research on Osteonecrosis and venous thromboembolism in children and adolescent with Hodgkin’s lymphoma in Finland, Sweden and Denmark, between 2005-2019, grant of 30 000 euros.
Research on Randomized, Multi-Center Phase III Trial comparing two conditioning regimens in children with AML undergoing allogeneic HSCT, grant of 33 770 euros.
Research on CNS NHL flow add-on study, Central nervous system involvement in non-Hodgkin’s lymphoma among children and adolescents: Spinal fluid biomarkers and rituximab penetration, grant of 16 200 euros.
Research on Health-related quality of life in Non-Hodgkin Lymphoma in children and adolescents, grant of 13 800 euros.
2020
Grant of 30 000 euros to research on altered PP2A regulation of the epigenetic machinery in pediatric cancers.
Grant of 60 000 euros to research on late-effects of HR ALL.
Grant of 4 000 euros to research on AML related FLT3-ITD positive.
Grant of 3 500 euros to research on ALAL leukemia.
Grant of 4 000 euros to research on long-term psychosocial late-effects.
Grant of 3 000 euros to research on Notch signaling mechanism in relation to cancer development.
Grant of 69 617 euros to research on Loggic Core BioClinical and Loggic Europe Trial.
Grant of 24 000 euros to research in Pediatric Early Phase Trials Unit.
Grant of 6 000 euros to research on the determinants of drug response in childhood, adolescent and young adult acute lymphoblastic leukemia.
Grant of 47 483 euros to research on HR MB over 3 years old.
Grant of 18 200 euros to research on ALLTogether sub study about asparginase activity levels and outcome.
Grant of 70 000 euros to research consortium on childhood cancer protocol studies.
Grant of 20 000 euros to research on 3D-modeling of childhood osteosarcoma.
Grant of 49 000 euros to research on ALLTogether treatment study protocol.
Lasten ja nuorten veri- ja syöpätautien epidemiologia, psykososiaalisen hoitoprosessin ja hoito-ohjelmien kehittäminen TYKS:ssa, 70 000 euroa.
2019
Korkeariski neuroblastooman hoitoprotokolla (HR-NBL 2.0 SIOPEN), 41 000 euroa »
Ewingin sarkooman kansainvälisen hoito-ohjelman (iEuroEWING), 61 346 euroa »
SIOP PNET5 MB v12. Medulloblastooman postoperatiivinen hoito, 61 346 euroa »
Complement in pediatric hematopoietic stem cell transplantation, 25 000 euroa »
Lasten aivokasvainten hoitojen myöhäisvaikutukset, 7 000 euroa »
Lasten ja nuorten veri- ja syöpätautien epidemiologia, psykososiaalisen hoitoprosessin vaakiinnuttaminen, myöhäishaittariskialgoritmin luominen ja hoito-ohjelmien kehittäminen TYKS:ssa, 94 800 euroa.
ALLTogether treatment study protocol of the ALLTogether Consortium for children and young adults with newly diagnosed acute lymphoblastic leukaemia (ALL), grant of 129 500 euros.
Research on childhood cancer patients’ psychosocial post symptoms identifying enhanced by artificial intelligence, grant of 28 000 euros.
Research on the establishment of functional drug response profiling of pediatric solid tumors, grant of 13 800 euros.
Postdoc research on combination therapy of aggressive medulloblastoma, grant of 25 000 euros.
Dissertation thesis research on In-utero exposures and risk of childhood cancer in offspring, grant of 6 000 euros.
Dissertation thesis research on effects of allogenic bone marrow transplantation to respiration and virus infections, grant of 10 000 euros.
Research on relapsed and/or refractory childhood Ewingin sarcoma, grant of 6 750 euros.
Dissertation thesis research on Notch signaling mechanism in relation to cancer development, grant of 2 000 euros.
Research on Complement in pediatric hematopoetic stem cell transplantation, grant of 25 000 euros.
Research on Molecular Mechanisms and Novel Therapeutic Targets for hepatoblastoma, grant of 20 000 euros.
2018
LBL 2018 – kansainvälinen lasten lymfoblastilymfooman hoitoprotokolla, 212 100 euroa »
Kansainvälinen Langerhansin soluhistiosytoosi (LCH) hoitoprotokolla, LCH-IV, 6 000 euroa »
2017
ALL:n ylläpitohoidon tehostaminen allopurinolin avulla, 9 000 euroa »
Lasten syövän hoito-ohjelmien kehitys Taysissa, 20 000 euroa »
Lasten leukemian uusien hoitojen kehitys, 15 000 euroa »
PeeTu:ssa 2017 alkavat varhaisvaiheen lasten syöpälääketutkimukset, 15 000 euroa »
SIOP 2016 UMBRELLA hoitoprotokolla, 26 000 euroa »
Lasten varhaisvaiheen kliininen lääketutkimuskeskus, Pediatric Early Phase Trial Unit, 3 000 euroa »
2016
TYKSin lasten syöpäosaston hoidon kehityshakkeiden tukeminen vuonna 2016, 100 000 euroa »
LBL 2014 Registry – kansainvälinen lasten lymfoblastilymfoomaprotokolla, 20 000 euroa »